Title: Randomised Clinical Trial of Weekly vs. Triweekly Cisplatin Based Chemotherapy Concurrent with Radiotherapy in the Treatment of Locally Advanced Cervical Cancer
Authors: Dr Niharika Panda, Dr Subrata Bag, Dr Sagarika Samantaray, Dr Lucy Pattanayak, Dr Umakant Satapathy
DOI: https://dx.doi.org/10.18535/jmscr/v5i4.54
Abstract
Cervical cancer is the most common malignancy in women. The standard treatment for locally advanced surgically inoperable case is cisplatin based chemo-radiation as cisplatin is a better radio-sensitizer in comparison to 5FU. Weekly cisplatin 40mg/m2 chemotherapy is currently considered the standard regimen in locally advanced cervical cancer. Two Arms of patients (41 in each) suffering from carcinoma cervix were studied for their compliance & toxicity to the regimens of weekly cisplatin 40mg/m2 with concurrent radiation and tri-weekly cisplatin 75mg/m2 with concurrent radiation. The toxicities like haematological, gastrointestinal and dermatological and the response were compared. It is observed that the three weekly cisplatin 75mg/m2 chemotherapy concurrent with radiotherapy may be more effective and feasible and has comparable outcome with weekly cisplatin 40mg/m2 chemotherapy which is currently considered the standard regimen in locally advanced cervical cancer. The response may be due to higher peak concentration of cisplatin enhancing the synergy of chemo-radiation.
Keywords-cancer cervix, weekly vs tri-weekly cisplatin with concurrent radiation.
References
1. Garcia AA, Blessing JA, Darcy KM et al. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research. A Gynaecologic Oncology Group study. GynecolOncol 2007;104:572-579.
2. Keys HM, Bundy BN, Stehman FB et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N. Engl J Med, 1999; 340: 1154-1161.
3. Morris M, Eifel PJ, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high risk cervical cancer. N. Engl J Med, 1999; 340: 1137-1143.
4. Peters WA 3rd, Liu PY, Barret RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy alone as adjuvant therapy after radical surgery in high risk early stage cancer of the cervix. J Clin Oncol, 2000; 18: 1606-1613.
5. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl J Med, 1999; 340: 1144-1153.
6. Kirwan JM, Symonds P, Green JA, et al. A systrmatic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiotherapy Oncol 2003; 68:217-226
7. Lanciano R, Calkins A, Bundy BN, et al. Randomised comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer, a Gynaecological Oncology group study. J Clin Oncol 2005;23:8289-8295.
8. Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advance squamous cell cancer of cervix. J Clin Oncol 2002;20:966-972.
9. Bonomi P, Blessing JA, Stehman FB, et al. Randomised trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix. a Gynaecological Oncology group study. J Clin Oncol 1985;3:1079-1085.
10. Ikushima H, Osaki K, Furutani S, et al. Chemotherapy for cervical cancer. Toxicity of concurrent weekly cisplatin. Radiat Med 2006;24:115-121.
11. Mitsuhasi A, Uno T, Tanaka N et al. Phase I study of daily cisplatin and concurrent radiotherapy in patients with cervical carcinoma. Gynecol Oncol2005;96:194-197.
12. Sang-Young Ryu, Won-Moo Lee et al. Randomized trial of weekly vs tri-weekly cisplatin based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int. J. Radiation Oncology Biol Phys. 2011;8:(4), e577-e581.